Cellect Biotechnology, a developer of a stem cell production technology, has signed a collaboration and material transfer agreement with the denovoMATRIX group of the Technische Universität Dresden (TU Dresden).
Bristol-Myers Squibb (BMS) has announced that the European Commission (EC) has expanded the indication for Sprycel (dasatinib) to include the treatment of children and adolescents aged 1 year to 18 years with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP), and to include a powder for oral suspension formulation.
A failure in a phase 1 clinical program has forced Zynerba Pharmaceuticals to stop development of ZYN001, its pro-drug of tetrahydrocannabinol (THC) intended for the treatment of neuropsychiatric disorders including Tourette Syndrome.
The European Medicines Agency (EMA) has accepted Clovis Oncology’s marketing application for a new indication of Rubraca (rucaparib) as maintenance treatment for women with recurrent ovarian cancer.
NSF International provides a comprehensive range of support services for the pharmaceutical industry covering consulting, training, auditing, remediation, quality systems and regulatory guidance on a global basis.
ASLAN Pharmaceuticals has submitted a clinical trial authorisation application with the Singapore Health Sciences Authority (HSA) to initiate a phase 1 trial of ASLAN004.
Elite Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for generic Percocet (Oxycodone Hydrochloride and Acetaminophen, USP CII) 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets.
Anavex Life Sciences has secured approval from the Australian Human Research Ethics Committee to begin its phase 2b/3 trial of Anavex 2-73 to treat early Alzheimer’s disease.
Fortress Biotech announced that the US Food and Drug Administration (FDA) has granted fast track designation to Cyprium Therapeutics Copper Histidinate, also referred to as CUTX-101, for patients diagnosed with classic Menkes disease who have not demonstrated significant clinical progression.
US-based Aveo Pharmaceuticals and Swiss drugmaker Novartis have scrapped their $326m worth licensing agreement to develop and commercialize the former’s humanized inhibitory antibody AV-380 and other related antibodies.
News from Twitter
Great things happening at Tissue Regenix! Plan to visit our booth at the AAOS meeting in New Orleans, under the CellRight Technologies banner #5413. @AAOS1
All evaluation cases for the new Corin Dual Mobility option for the Trinity Acetabular cup system have now been completed and we're looking forward to the full launch. Click lnkd.in/g8ariEY for details #orthopaedics #technology #totalhip #uniquehip pic.twitter.com/SPsy…
#cardiovascular news CorFlow Presents Fundamental New Insights into the Coronary Microcirculation at ACC - CorFlow Therapeutics AG corflowtherapeutics.… today announced that the company will present fundamental new insights into the coronary microci... ow.ly/OlaG50gAElO
Read in this edition all about Novartis Oncology’s ground-breaking CAR-T therapy; how SwissMedic is leading the world in terms of regulatory innovation; the story of Actelion’s acquisition by J&J and the subsequent emergence of a new entity – Idorsia. pharmaboardroom.com/…
Thème du congrès SOFCOT 2018 : "La Décision Médicale" pic.twitter.com/hJT5…
Exactly 3 weeks left to submit your abstract for #EUROSPINE2018 - #deadline 1 March 2018 #research #spine #SpineResearch #spineSurgery #SpinalDisorder #ScientificPaper #BasicScience #ClinicalResearch #PublishResearch @EurSpineJournal buff.ly/2ExMQ7e pic.twitter.com/Fx2Q…
Throughout the week, we are in #Bruges alongside Prof. Jan Casselman for an #Erasmus course program on #ENT imaging, held at the Oud Sint-Jan congress centre. The training of around 170 radiologists is based on images from our post-processing solution Olea Sphere®V3.0. #MRI pic.twitter.com/KSUU…
#ArtificialIntelligence is currently in the center of all discussions, medical #imaging including. What will be impacted, notably in #MSK imaging? Listen to the answer of Pr Cotten from Lille’s CHRU : youtu.be/93nLXGX4hEk
Did you know our IRIS technology may reduce ureteral injury rates by up to an estimated 49%? Protect your patient & reduce risk in the OR! pic.twitter.com/koeJ…
Wishing Medtronic co-founder Earl Bakken a very happy 94th birthday. Best wishes to you, Earl! pic.twitter.com/zdDa…
European investment group LSP closes $330m healthcare fund captis.com/?p=36537
CHF Solutions closes $18m Series F round captis.com/?p=36109
BD tacks another extension onto Bard tender offer captis.com/?p=36138
Boston Scientific takes a $3B hit on latest Lotus valve delay captis.com/?p=36199
Zebra Medical Vision to host AI1 image analytics on Google Cloud captis.com/?p=35413
Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News